动态增强磁共振成像定量参数对乳腺癌新辅助化疗疗效评价及相关性研究

李娜; 王丹丹; 罗娅红; 崔凤娇; 李琳; 白浩言

doi:10.19732/j.cnki.2096-6210.2020.03.022

您当前的位置：

首页 >

文章列表页 >

动态增强磁共振成像定量参数对乳腺癌新辅助化疗疗效评价及相关性研究

论著 | 更新时间：2025-12-15

- 动态增强磁共振成像定量参数对乳腺癌新辅助化疗疗效评价及相关性研究
- The application value of dynamic contrast-enhanced magnetic resonance imaging quantitative parameters in the evaluation of the efficacy of neoadjuvant chemotherapy for breast cancer and its correlation with biological prognostic factors
- 肿瘤影像学 2020年29卷第3期页码：330-335
- 作者机构：
  
  辽宁省肿瘤医院医学影像科,辽宁,沈阳,110042
- 作者简介：
- 基金信息：
  
  国家公益性行业科研专项（201402020）
- DOI：10.19732/j.cnki.2096-6210.2020.03.022
  中图分类号：
- 网络出版：2020-06-28，
  
  纸质出版：2020-06-28
- 稿件说明：
移动端阅览
李娜,王丹丹,罗娅红,等. 动态增强磁共振成像定量参数对乳腺癌新辅助化疗疗效评价及相关性研究[J]. 肿瘤影像学, 2020, 29(3): 330-335 https://doi.

org/10.19732/j.cnki.2096-6210.2020.03.022
李娜,王丹丹,罗娅红,等. 动态增强磁共振成像定量参数对乳腺癌新辅助化疗疗效评价及相关性研究[J]. 肿瘤影像学, 2020, 29(3): 330-335 https://doi. DOI： 10.19732/j.cnki.2096-6210.2020.03.022.

org/10.19732/j.cnki.2096-6210.2020.03.022 DOI：

摘要

目的：

探讨动态增强磁共振成像（dynamic contrast-enhanced magnetic resonance imaging，DCE-MRI）定量参数及相关生物学因子的表达评估乳腺癌术前新辅助化疗疗效的应用价值。

方法：

回顾并收集临床资料完整且术前行新辅助化疗的女性乳腺癌患者56例，根据实体瘤疗效评价标准（Response Evaluation Criteria in Solid Tumor，RECIST）分为治疗有效和无效两组，比较两组化疗前、２个疗程后、化疗结束时的容量转移常数（K

trans

）、速率常数（K

）、血浆容积分数（V

值）。采用免疫组化染色法检测乳腺癌组织雌激素受体（estrogen receptor，ER）、孕激素受体（progesterone receptor，PR）、人表皮生长因子受体２（human epidermal growth factor receptor 2，HER2）及Ki-67表达情况，并分析不同表达状态时DCE-MRI定量参数的大小及DCE-MRI定量参数与Ki-67表达之间的相关性。

结果：

治疗有效组K

trans

max、K

trans

mean、K

max、K

mean值在2个疗程后及化疗结束时均明显低于治疗前（

＜0.05），K

trans

min值在化疗结束时较治疗前明显降低（

＜0.05）。ER、PR阴性组的K

max、K

mean值高于ER、PR阳性组（

＜0.05）；PR阴性组的V

max值高于PR阳性组（

＜0.05）。Ki-67表达与K

trans

min、K

trans

max值及K

trans

mean值呈正相关（

=0.384，

=0.003；

=0.294，

=0.028；

=0.551，

＜0.01），Ki-67表达与K

、V

值无相关性（

＞0.05）。

结论：

DCE-MRI定量参数及相关生物学因子的表达可对乳腺癌患者新辅助化疗疗效进行评估，值得临床推广应用。

Abstract

Objective:

To evaluate the value of dynamic contract-enhanced magnetic resonance imaging (DCE-MRI) quantitative parameters and the expression of related biological factors in the evaluation of the efficacy of neoadjuvant chemotherapy for breast cancer.

Methods:

A total of 56 female patients with breast cancer were recruited

all of them had complete clinical data and undertake neoadjuvant chemotherapy. In this study

they were divided into effective and ineffective groups according to the Response Evaluation Criteria in Solid Tumor (RECIST) criteria. The values of K

trans

and V

before

after two courses and at the end of chemotherapy were compared. Immunohistochemical staining was used to detect the expression of estrogen receptor (ER)

progesterone receptor (PR)

human epidermal growth factor receptor 2 (HER2) and Ki-67 in breast cancer tissues

and the size of DCE-MRI quantitative parameters in different expression states was analyzed. The correlation between the quantitative parameters of DCE-MRI and the expression of Ki-67 was analyzed.

Results:

The K

trans

max

trans

mean

max

and K

mean expression in the effective group were significantly decreased than those before neoadjuvant chemotherapy (

＜0.05). The K

trans

min expression was significantly lower at the end of chemotherapy than before neoadjuvant chemotherapy (

＜0.05). The K

max and K

mean values in the ER-expressionand PR-expression negative groups were higher than those in the ER-expression and PR-expression positive groups (

＜0.05). The V

max value in the PR-negative group wer

e higher than those in the PR-negative positive group (

＜0.05). Ki-67 expression was positively correlated with K

trans

min

trans

max and K

trans

mean values (

=0.384

=0.003;

=0.294

=0.028;

=0.551

＜0.01). There was no correlation between the value of K

and Ki-67 expression (

＞0.05).

Conclusion:

The quantitative parameters of DCE-MRI and the expression of related biological factors can evaluate the efficacy of neoadjuvant chemotherapy in breast cancer patients

which is worthy of clinical application.

关键词

Keywords

references

浏览量

1406

下载量

CNKI被引量

文章被引用时，请邮件提醒。

提交

工具集

关联资源

预测乳腺癌疗效的多期MRI直方图阵列方法

超声联合临床病理学特征的列线图评分模型对HER2阳性乳腺癌NAC后pCR的预测价值

乳腺癌新辅助化疗前后钙化改变的临床应用价值

乳腺癌动态增强磁共振成像纹理分析对新辅助化疗疗效预测与评估研究

动态增强磁共振成像定量参数早期预测局部进展期乳腺癌新辅助化疗效果的价值